Mylan, Teva Win Again on Allergan Ulcer Drug Patent

Teva Pharmaceutical USA Inc. and Mylan Pharmaceuticals Inc. notched a win that may have moved them closer to launching generic versions of Allergan Plc’s ulcer treatment Delzicol.

The U.S. Court of Appeals for the Federal Circuit affirmed without opinion a district court ruling finding Mylan and Teva’s proposed generics didn’t infringe Allergan’s patent. Delzicol treats mild to moderately active ulcerative colitis. According to Symphony Health data reported by Bloomberg Intelligence, the drug had sales of approximately $273. 2 million in 2017.

The generic makers still have to obtain final Food and Drug Administration approval for their products before they can ...